Akzo Nobel dropped its Q3 2026 scorecard with a jolt. The stock closed at €60.96 on the day of the release, roughly flat over the past week and month, yet the headline result was a reported loss of €177m, or basic earnings per share of €1.04 in the red. That clash between a steady share price and a swing into the red is the market's sentiment test.
Traders appear to be focusing on the clearer picture of a 15.3% adjusted EBITDA margin and six straight quarters of improvement, while the income statement loss is harder to digest. Market reaction is balancing perceived resilience with the impact of the profit squeeze.
Love the improving 15.3% adjusted EBITDA margin at Akzo Nobel but worried about an income statement that just swung to a €177m loss? Benchmark that mix of profitability and resilience against our list of solid balance sheet and fundamentals stocks (203 results) .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):€2,538m vs. €2,547m (broadly flat top line year on year)
-
Net Income/Loss (Q3 2026 vs. Q3 2025):loss of €177m vs. loss of €193m (slightly smaller quarterly loss)
-
Basic EPS (Q3 2026 vs. Q3 2025):loss of €1.04 per share vs. loss of €1.13 per share (loss per share narrowed)
-
Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025):15.3% vs. a lower margin in the prior year, with six consecutive quarters of margin improvement
Earnings are one thing, but if you care about what you are actually paying for Akzo Nobel, then the cash that flows through the business matters more than any single quarterly print. On Akzo Nobel's cash flows alone, the stock could be a hefty 45% undervalued .
Evaluating Akzo Nobel's Earnings Recovery Claims
The bullish story hinges on Akzo Nobel squeezing more profit out of a subdued volume backdrop rather than relying on a boom in demand.
"Execution of the SG&A and Industrial Excellence programs, with a combined €0.5b of gross cost takeout and carryover benefits into 2026 and 2027, is set to create meaningful operating leverage as volumes stabilize."
Q3 results line up with that ambition. Volumes declined about 2%, yet adjusted EBITDA reached €388m and margin held at 15.3% with six consecutive quarters of improvement. Management kept the €1.47b full year adjusted EBITDA target and highlighted site closures and working capital discipline, which suggests the cost programs are delivering tangible operating leverage so far.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there .
Akzo Nobel Bear Case: Execution Risks Still Unproven
Bearish investors worry that Akzo Nobel can talk a good cost story but fail to turn programs into reliable earnings quality.
"The €500 million cost takeout from SG&A and industrial programs, including 2,900 position reductions and at least €300 million of industrial savings, is designed to create operating leverage on any eventual volume recovery and affect margins and earnings quality."
Q3 shows pricing and cost work holding margins at 15.3% despite a 2% volume decline. However, the reported €177m loss and modest free cash flow of €83m year to date mean clean earnings and cash conversion are not yet matching the efficiency narrative.
Hunt For Quiet Earnings Disconnects
Akzo Nobel shows how margins and reported profit can tell very different stories in a single quarter. The real opportunity is finding stocks that could be undervalued before the market corrects them.
-
Company 1 - 18% below our estimate - focuses on secured retail lending while lifting business per employee as headcount edges lower.
-
Company 2 - 49% below our estimate - tightens coverage on problem loans, building extra protection if key economies eventually cool.
-
Company 3 - 41% below our estimate - expands composite content and aftermarket work as aircraft programs ramp and new mobility projects require lighter structures.
Those are three of them. See every one of the 190 undervalued companies on it →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AKZA.AS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
